Additionally, PX-478, which is a potent small-molecule HIF-1α inhibitor, had a substantial anticancer effect in two adenocarcinoma models, PC14-PE6 and NCI-H441, and two small cell lung cancer (SCLC) models, NCI-H187 and NCI-N41 (92). This evidence concerns the gene HIF1A and adenocarcinoma.